Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Capitalistaon Aug 14, 2022 11:03am
161 Views
Post# 34895001

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Get ready for more merger mania in the pharma sector

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Get ready for more merger mania in the pharma sector With all due respect, Notable, I'm not following your logic.  To my mind, having 12 years' marketing exclusivity is the very definition of timebound.  However, each separate combo of pela with another agent would start a separate 12-year exclusivity period; is this what you mean?  In that sense it is similar to a mining company discovering a new ore body (which they all try to do to extend mine life and/or throughput). 

In any case, I'm not worried.  Even if Pela had only one combo (with, say, Bavencio) for twelve years, that would likely be enough to justify the $8 to $15 billion valuation being bandied about.  The rest is just icing on the cake for the BP. 
<< Previous
Bullboard Posts
Next >>